TW202342478A - 二醯基甘油激酶(DGK)α抑制劑及其用途 - Google Patents

二醯基甘油激酶(DGK)α抑制劑及其用途 Download PDF

Info

Publication number
TW202342478A
TW202342478A TW112107273A TW112107273A TW202342478A TW 202342478 A TW202342478 A TW 202342478A TW 112107273 A TW112107273 A TW 112107273A TW 112107273 A TW112107273 A TW 112107273A TW 202342478 A TW202342478 A TW 202342478A
Authority
TW
Taiwan
Prior art keywords
heterocycloalkyl
alkyl
cycloalkyl
aryl
heteroaryl
Prior art date
Application number
TW112107273A
Other languages
English (en)
Chinese (zh)
Inventor
陸洪福
余華星
丁曉
任峰
Original Assignee
香港商英矽智能科技知識產權有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 香港商英矽智能科技知識產權有限公司 filed Critical 香港商英矽智能科技知識產權有限公司
Publication of TW202342478A publication Critical patent/TW202342478A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TW112107273A 2022-03-01 2023-03-01 二醯基甘油激酶(DGK)α抑制劑及其用途 TW202342478A (zh)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
CN2022078655 2022-03-01
WOPCT/CN2022/078655 2022-03-01
WOPCT/CN2022/091215 2022-05-06
CN2022091215 2022-05-06
CN2022128282 2022-10-28
WOPCT/CN2022/128282 2022-10-28
CN2023071962 2023-01-12
WOPCT/CN2023/071962 2023-01-12

Publications (1)

Publication Number Publication Date
TW202342478A true TW202342478A (zh) 2023-11-01

Family

ID=87883015

Family Applications (1)

Application Number Title Priority Date Filing Date
TW112107273A TW202342478A (zh) 2022-03-01 2023-03-01 二醯基甘油激酶(DGK)α抑制劑及其用途

Country Status (7)

Country Link
US (1) US20250214990A1 (cg-RX-API-DMAC7.html)
EP (1) EP4486745A4 (cg-RX-API-DMAC7.html)
JP (1) JP2025507915A (cg-RX-API-DMAC7.html)
CN (1) CN118829642A (cg-RX-API-DMAC7.html)
AR (1) AR128668A1 (cg-RX-API-DMAC7.html)
TW (1) TW202342478A (cg-RX-API-DMAC7.html)
WO (1) WO2023165509A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL315015A (en) 2022-03-01 2024-10-01 Insilico Medicine Ip Ltd Diacylglycerol kinase (DGK) alpha inhibitors and their uses
TW202436351A (zh) 2023-02-06 2024-09-16 德商拜耳廠股份有限公司 Ccr8抗體及dgk抑制劑之組合
CN122094689A (zh) * 2023-09-04 2026-05-26 英矽智能科技知识产权有限公司 二酰甘油激酶(DGK)α抑制剂与其他疗法的组合治疗

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011075747A1 (en) * 2009-12-18 2011-06-23 Glaxosmithkline Llc Therapeutic compounds
CN112654621B (zh) * 2018-06-27 2024-05-14 百时美施贵宝公司 可作为t细胞活化剂的经取代萘啶酮化合物
WO2021105115A1 (en) * 2019-11-28 2021-06-03 Bayer Aktiengesellschaft Substituted aminoquinolones as dgkalpha inhibitors for immune activation
IL294148A (en) * 2019-12-23 2022-08-01 Bristol Myers Squibb Co Substituted quinazolinyl compounds are useful as t-cell activators
CN115362003B (zh) * 2019-12-24 2024-03-22 卡尔那生物科学株式会社 二酰基甘油激酶调节化合物
MX2023014762A (es) * 2021-06-23 2024-01-15 Gilead Sciences Inc Compuestos moduladores de diacilglicerol quinasa.

Also Published As

Publication number Publication date
CN118829642A (zh) 2024-10-22
EP4486745A4 (en) 2026-03-11
EP4486745A1 (en) 2025-01-08
US20250214990A1 (en) 2025-07-03
AR128668A1 (es) 2024-06-05
JP2025507915A (ja) 2025-03-21
WO2023165509A1 (en) 2023-09-07

Similar Documents

Publication Publication Date Title
JP7716110B2 (ja) ピリミジン-4(3h)-オンヘテロ環式化合物、その調製方法、およびその医薬的使用
AU2023254280A1 (en) Fused ring compound, pharmaceutical composition containing same, and use of fused ring compound
CA3226720A1 (en) Kras g12d inhibitors and uses thereof
TW202342477A (zh) 二醯基甘油激酶(DGK) α抑制劑及其用途
KR20110117195A (ko) 단백질 키나제 억제제로서의 화합물
JP7218431B2 (ja) 環状ジヌクレオチド類似体、その医薬組成物及び使用
CN118829642A (zh) 二酰基甘油激酶(DGK)α抑制剂及其用途
CN115043836B (zh) 一种咪唑并吡啶衍生物的p2x3受体选择性调节剂及其药物用途
TW202521544A (zh) TNFα活性調節劑及其用途
WO2023165525A1 (en) Diacylglycerol kinase (dgk) alpha inhibitors and uses thereof
KR20240093606A (ko) 치환된 1H-피라졸로[4,3-c] 퀴놀린, 이의 제조 방법 및 용도
TWI894448B (zh) Ctla-4小分子降解劑及其應用
TW202416963A (zh) Egfr抑制劑及其用途
AU2023224815A1 (en) Compound as fak inhibitor and use thereof
TW202218661A (zh) 作為egfr抑制劑的三環化合物
EA052540B1 (ru) Ингибиторы альфа-диацилглицеринкиназы (дгк) и способы их применения
JP7384669B2 (ja) 置換ジヒドロピロロピラゾール化合物および免疫療法剤が組み合わせて投与される医薬組成物
HK40117800A (en) Diacylglycerol kinase (dgk) alpha inhibitors and uses thereof
CN119490507A (zh) 一种新型激酶抑制剂
CN120712269A (zh) Fgfr2和fgfr3的抑制剂及其用途
HK40055645B (en) Cyclic dinucleotide analogue, pharmaceutical composition thereof, and application
HK40055645A (en) Cyclic dinucleotide analogue, pharmaceutical composition thereof, and application
HK40032239A (en) Receptor inhibitors, pharmaceutical compositions comprising the same and use thereof
BR112020001124B1 (pt) Composto ou o sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e uso do composto ou do sal farmaceuticamente aceitável do mesmo
EA041924B1 (ru) Аналог циклического динуклеотида, его фармацевтическая композиция и применение